BelaCarD Study (AMaRC 19-02)
This is a phase I/II open label single arm clinical study. Patients with Relapsed/Refractory Multiple Myeloma who have had 1 to 3 prior lines of treatment, will receive Belantamab Mafodotin in combination with carfilzomib and dexamethasone. (BelaCarD)
There will be two phases in the study. The first, safety, run-in phase will consist of 10 patients. After the 10th evaluable patient has completed the 1st cycle, the trial management committee (TMC) will hold a meeting to assess whether or not there are any safety concerns at that dosing schedule. Provided that no more than 4 patients experience a grade 4, treatment-emergent toxicity, and subject to the confirmatory advice from the Data Safety and Monitoring Committee (DSMC), the expansion phase will commence at the same treatment dose and schedule.
For more information please visit
Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)
Other (specify below)
Parts of research done:
Addition of sites for study recruitment